New SARS-CoV-2 variants mean new neutralizing antibodies to deal with them. With the COVID-19 pandemic on its third wave in some countries, the rise of variants has triggered a new wave of research into neutralizing antibodies, in a bid to maintain – or at least gain – control of the virus. The new variants exhibit mutations in the receptor-binding domain (RBD) of the spike protein, which has been a mainstay for drug developers thus far. Studies have demonstrated that neutralizing antibodies are less efficacious against variants with mutations in the RBD – which include the B.1.1.7 (first identified in the UK), B.1.351 (first identified in South Africa) and P.1 (first identified in...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!